Session 1: Keynote: New Treatment Strategies in DLBCL

Dr Laurie Sehn is currently Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She completed a fellowship in Hematology-Oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University. Prior to returning to Canada, she spent a year as faculty at the Dana-Farber Cancer Institute with the Bone Marrow Transplantation service. Dr. Sehn’s research interests include population-based outcomes analyses, identification of prognostic factors and predictive biomarkers, and development of novel therapies in lymphoma. Dr Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. She has also served as a member of the editorial board of Journal of Clinical Oncology and Leukemia Lymphoma, and as an Associate Editor and Podcast Editor for Blood. Dr. Sehn also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group and co-chair of the Lunenburg Lymphoma Biomarker Consortium.